News & Videos - AGILE THERAPEUTICS INC. - English

STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Agile Therapeutics, Inc. - AGRX PR Newswire NEW YORK, July 3, 2024 NEW YORK , July 3, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Agile Therapeutics, Inc. (OTCQB:...

Thinking about buying stock in Agile Therapeutics, Nano-X Imaging, Eastside Distilling, Root Inc, or GigaCloud Technology? PR Newswire NEW YORK, Feb. 22, 2024 NEW YORK , Feb. 22, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AGRX, NNOX, EAST, ROOT, and GCT. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. AGRX:...

PRINCETON, NJ / ACCESSWIRE / November 22, 2023 / Agile Therapeutics, Inc. (NASDAQ:AGRX), the commercial-stage women's healthcare company, posted a 122% increase in third-quarter revenue year-over-year, driven by strong demand for TwirlaⓇ (levonorgestrel and ethinyl estradiol) transdermal system, its birth control patch. The company also reiterated its target for full-year 2023 revenue of at least $25 million and to be cash flow positive from operations in the first quarter of 2024. "In the...

PRINCETON, NJ / ACCESSWIRE / September 28, 2023 / Maxim Group , a major investment bank, conducts and publishes stock analysis through its Equity Research team. The team has a strong reputation in the industry; a host of major firms use its research. The firm's focus and area of expertise is in small and micro-cap companies, some of which are poised for growth. In a recent report , the research team at Maxim Group outlined why it has upgraded Agile Therapuetics Inc. (NASDAQ:AGRX) to a "buy"...

PRINCETON, NJ / ACCESSWIRE / August 17, 2023 / On August 9, Agile Therapeutics (NASDAQ:AGRX) released its second-quarter financial results, showing significant growth in revenue from its innovative weekly birth control patch, Twirla® (levonorgestrel and ethinyl estradiol), and a widening gross margin thanks to net revenue growth and decreasing operating expenses. "We set single-quarter record highs in demand, net revenue and factory sales, all while reporting another quarterly decrease in...

PRINCETON, NJ / ACCESSWIRE / July 19, 2023 / Agile Therapeutics, Inc.'s (NASDAQ:AGRX) partnership with Afaxys Pharma is expected to play a key role in propelling the women's healthcare company toward its $25-$30 million net annual revenue target for 2023. The companies teamed up last year to make Twirla® (levonorgestrel and ethinyl estradiol) transdermal system, Agile's low-dose contraceptive patch available to the more than 15,000 health centers that Afaxys serves. Community And Public Health...

PRINCETON, NJ / ACCESSWIRE / July 18, 2023 / This month, Agile Therapeutics, Inc. (NASDAQ:AGRX) announced partnerships with FPA Women's Health and vitaCare Prescription Services that will expand access to Twirla® (levonorgestrel and ethinyl estradiol) transdermal system, its low-dose weekly birth control patch. The news builds on earlier partnerships that have been steadily making the patch more available, including an agreement signed in August of last year making Twirla available on the Nurx...

PRINCETON, NJ / ACCESSWIRE / July 11, 2023 / - In June, President Biden issued an Executive Order on Strengthening Access to Affordable, High-Quality Contraception and Family Planning Services . It directs the Secretaries of Health and Human Services (HHS), Labor and the Treasury to issue new guidance that ensures all contraceptives approved by the Food and Drug Administration (FDA) are covered without cost-sharing by private health insurance. The order also directs the departments to take...

PRINCETON, NJ / ACCESSWIRE / July 5, 2023 / H.C. Wainwright & Co, reiterated its buy rating on Agile Therapeutics, Inc. (NASDAQ:AGRX) this month, setting a price target of $12 per share. The $12 price target is based on the 1:50 reverse split and the $7.5 million raised in Agile's public offering in May. Despite challenges faced by the women's healthcare company, its patented weekly birth control patch has seen a steady increase in demand, and the company is leveraging key partnerships to expand...

Agile Says Growing Demand For Twirla (levonorgestrel and ethinyl estradiol ) transdermal system Is Helping It Stay On Track to Hit $25-$30 Million Net Revenue PRINCETON, NJ / ACCESSWIRE / July 3, 2023 / Agile Therapeutics (NASDAQ:AGRX) announced the closing of its public offering in May. The women's healthcare company raised $7.5 million in gross proceeds after selling over 1.8 million shares of common stock at $3.95 per share. The offering came just weeks after Agile released its first quarter...

PRINCETON, NJ / ACCESSWIRE / June 30, 2023 / Women are itching for more birth control options that cater to their unique needs and preferences. While traditional forms of birth control - such as the pill and condoms - have been reliable options for many years, they don't satisfy everyone. For example, a recent study showed that of the top 100 most viewed TikToks tagged #IUDs, 37.8% had a negative tone and 27.6% had a distrust of healthcare professionals. Women, especially younger women, are less...

PRINCETON, NJ / ACCESSWIRE / June 28, 2023 / The invention of birth control in the 1960s revolutionized women's health and their lives. In 2022, the contraceptive market was valued at $8.3 billion and it is projected to grow at a compound annual growth rate (CAGR) of around 5.16% from 2023 to 2030. With the overturning of Roe v Wade, birth control has now become more important than ever. The decision and conversations around stricter birth control rules have resulted in a higher demand for birth...

EQS-News: Agile Therapeutics, Inc. This Biotech Company is Pursuing Positive Cash Flow In 2023 21.12.2022 / 15:05 CET/CEST The issuer is solely responsible for the content of this announcement. Biotech company Agile Therapeutics Inc. (NASDAQ: AGRX) began selling its contraceptive patch in 2021, and the company is pursuing positive cash flow by the end of 2023. The Princeton, New Jersey-based company’s Twirla patch gives women the choice to not take a birth control pill every day. Instead,...

EQS-News: Agile Therapeutics, Inc. Women’s Healthcare Company Agile Therapeutics Says It Believes It Has An Effective Business Plan In Place For Growth And Generating Positive Cash Flow 15.11.2022 / 14:15 CET/CEST The issuer is solely responsible for the content of this announcement. Agile Therapeutics Inc. (NASDAQ: AGRX) is on a journey to fulfill the unmet health needs of women with products designed to provide them with contraceptive options. The company’s product and product candidates...

EQS-News: Agile Therapeutics, Inc. Can This Company’s Birth Control Patch Disrupt The Contraceptive Market? 26.10.2022 / 14:00 CET/CEST The issuer is solely responsible for the content of this announcement. From Evofem Biosciences Inc. ’s (OTCMKTS: EVFM) Phexxi vaginal gel contraceptive to Dare Bioscience Inc. ’s (NASDAQ: DARE) Ovaprene, an investigational hormone-free monthly intravaginal contraceptive, the market is never in short supply of birth control products. While the issue of...

EQS-News: Agile Therapeutics, Inc. NASDAQ: AGRX Agile Therapeutics Anticipates Increased Growth In Q3 of 2022 21.10.2022 / 17:00 CET/CEST The issuer is solely responsible for the content of this announcement. Contact Details Matt Riley - Head of Investor Relations & Corporate Communications [email protected] Company Website https://agiletherapeutics.com/ News Source: News Direct 21.10.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG....

Thinking about buying stock in Agile Therapeutics, AMC Entertainment, AT&T, Ocugen, or Visa? PR Newswire NEW YORK, June 29, 2022 NEW YORK , June 29, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AGRX, AMC, T, OCGN, and V. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. AGRX:...

Thinking about buying stock in Kezar Life Sciences, Evofem Biosciences, Agile Therapeutics, Sutro Biopharma, or Wejo Group? PR Newswire NEW YORK, June 28, 2022 NEW YORK , June 28, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for KZR, EVFM, AGRX, STRO, and WEJO. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. KZR:...

Thinking about buying stock in Epizyme, Acutus Medical, Agile Therapeutics, Axsome Therapeutics, or Evofem Biosciences? PR Newswire NEW YORK, June 27, 2022 NEW YORK , June 27, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for EPZM, AFIB, AGRX, AXSM, and EVFM. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. EPZM:...

Thinking about buying stock in American Airlines, Petroleo Brasileiro, Agile Therapeutics, Uranium Energy, or Ginkgo Bioworks? PR Newswire NEW YORK, April 14, 2022 NEW YORK , April 14, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AAL, PBR, AGRX, UEC, and DNA. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. AAL:...